arrow
L

Lorenzo Castagnoli

amadeolab fondazione irccs istituto nazionale dei tumori di milano
H指数:21
被引数:1,171

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

CD36富集在HER2阳性间充质干细胞中,驱动乳腺癌的治疗抵抗性

2025-01-201
OA
Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution

乳腺癌患者衍生的类器官,用于研究患者特异性肿瘤的演变

2024-06-270
OAAI
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
2022-07-0515
OA
High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study
2022-02-151
PRE
The landscape of d16HER2 splice variant expression across HER2-positive cancers (vol 9, 3545, 2019)

HER2-positive癌症中d16HER2剪接变体表达的景观 (第9卷,3545卷,2019)

2020-04-240
OAAI
Fatty acid uptake as a potentially new resistance mechanism to anti-HER2 treatments in HER2-positive breast cancer
2020-02-150
PRE
The landscape of d16HER2 splice variant expression across HER2-positive cancers

HER2-positive癌症中d16HER2剪接变体表达的前景

2019-03-0526
OAAI
Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)

全身和肿瘤脂质代谢对依维莫司在晚期胰腺神经内分泌肿瘤 (pNETs) 中的疗效的影响

2019-01-0724
OAAI